Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-aminopyridine for nerve injury after prostatectomy
NCT03658408Phase 2Withdrawn
- Sponsor
- University of Rochester
- Start
- Oct 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in peripheral nerve injury (PNI), erectile dysfunction (ED) and urinary incontinence (UI) comparing 4-aminopyridine with Placebo (2 arms). Primary endpoint: percentage of participants with normal erectile dysfunction at 2 months. Planned start Oct 2018; status: withdrawn.
02
Drugs
dalfampridine
03
Conditions
peripheral nerve injury (PNI)erectile dysfunction (ED)urinary incontinence (UI)
Beyond the preview
Go deeper on NCT03658408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03658408.